Medipost, a Korea-based stem cell biotechnology company, agreed to acquire a 39.6% stake in OmniaBio, a contract development and manufacturing company for cell and gene therapy products, for C$30m ($24m). “OmniaBio, a verified CDMO company for cell and gene therapy products, needed to expand its business to Asia, and our company had an eye on the North American market for our CDMO business. This investment went through seamlessly because the two companies had the same intentions," Medipost.